{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:34:31Z","timestamp":1787578471216,"version":"build-2736575974"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ric.2026.100047","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:53:52Z","timestamp":1783446832000},"page":"100047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Huntington's disease in the era of somatic instability, biomarkers, and targeted therapies: A narrative review"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-9278","authenticated-orcid":false,"given":"Amin","family":"Cervantes-Arriaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Xanat","family":"Beltr\u00e1n-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4484-3404","authenticated-orcid":false,"given":"Diego","family":"Romero-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-9941","authenticated-orcid":false,"given":"Mayela","family":"Rodr\u00edguez-Violante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0535","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/cont.0000000000001597","article-title":"Huntington disease and chorea","volume":"31","author":"Moore","year":"2025","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0540","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington's disease: a clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2024.100200","article-title":"Huntington's disease: a clinical primer for acute and general physicians","volume":"24","author":"Massey","year":"2024","journal-title":"Clin Med"},{"issue":"19","key":"10.1016\/j.ric.2026.100047_bib0550","doi-asserted-by":"crossref","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","article-title":"Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease","volume":"96","author":"McAllister","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0555","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13167-024-00368-2","article-title":"Unraveling progression subtypes in people with Huntington's disease","volume":"15","author":"Raschka","year":"2024","journal-title":"EPMA J"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0560","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib0565","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.3390\/ijms25073845","article-title":"Huntington's disease: complex pathogenesis and therapeutic strategies","volume":"25","author":"Tong","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0570","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ric.2026.100047_bib0575","doi-asserted-by":"crossref","first-page":"8808","DOI":"10.1074\/jbc.M109.075028","article-title":"Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease","volume":"285","author":"Landles","year":"2010","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0580","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ric.2026.100047_bib0585","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/s41598-017-01510-z","article-title":"The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients","volume":"7","author":"Neueder","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0590","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/WNL.0000000000002858","article-title":"Huntington disease reduced penetrance alleles occur at high frequency in the general population","volume":"87","author":"Kay","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ric.2026.100047_bib0595","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1038\/gim.2014.146","article-title":"American College of Medical Genetics and Genomics standards and guidelines for clinical genetics laboratories, 2014 edition: technical standards and guidelines for Huntington disease","volume":"16","author":"Bean","year":"2014","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0600","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3892\/etm.2016.3566","article-title":"Huntington's disease: molecular basis of pathology and status of current therapeutic approaches","volume":"12","author":"Huang","year":"2016","journal-title":"Exp Ther Med"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0605","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/genes15060807","article-title":"Beyond CAG repeats: the multifaceted role of genetics in Huntington disease","volume":"15","author":"Pengo","year":"2024","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0610","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ng0893-393","article-title":"Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease","volume":"4","author":"Snell","year":"1993","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0615","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington's disease","volume":"162","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0620","article-title":"CAG repeat not polyglutamine length determines timing of Huntington's disease onset","volume":"178","year":"2019","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0625","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","article-title":"Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease","volume":"104","author":"Wright","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0630","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JHD-200427","article-title":"Huntington's disease pathogenesis: two sequential components","volume":"10","author":"Hong","year":"2021","journal-title":"J Huntingtons Dis"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.11.038","article-title":"Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease","volume":"188","author":"Handsaker","year":"2025","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0640","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/JHD-200445","article-title":"What is the pathogenic CAG expansion length in Huntington's disease?","volume":"10","author":"Donaldson","year":"2021","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0645","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JHD-200438","article-title":"DNA mismatch repair and its role in Huntington's disease","volume":"10","author":"Iyer","year":"2021","journal-title":"J Huntingtons Dis"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0650","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41588-025-02191-5","article-title":"Genetic modifiers of somatic expansion and clinical phenotypes in Huntington's disease highlight shared and tissue-specific effects","volume":"57","year":"2025","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ric.2026.100047_bib0655","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/brain\/awae063","article-title":"A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease","volume":"147","author":"Aldous","year":"2024","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0660","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3892\/br.2022.1587","article-title":"Recent approaches on Huntington's disease (Review)","volume":"18","author":"Palaiogeorgou","year":"2022","journal-title":"Biomed Rep"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib0665","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024240","article-title":"Huntington's disease: mechanisms of pathogenesis and therapeutic strategies","volume":"7","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"18","key":"10.1016\/j.ric.2026.100047_bib0670","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1111\/febs.12418","article-title":"Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis","volume":"280","author":"Lee","year":"2013","journal-title":"FEBS J"},{"issue":"5529","key":"10.1016\/j.ric.2026.100047_bib0675","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.ric.2026.100047_bib0680","doi-asserted-by":"crossref","first-page":"16798","DOI":"10.3390\/ijms242316798","article-title":"Mutant-Huntingtin molecular pathways elucidate new targets for drug repurposing","volume":"24","author":"Makeeva","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.ric.2026.100047_bib0685","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","author":"Kreisl","year":"2020","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.ric.2026.100047_bib0690","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5576","key":"10.1016\/j.ric.2026.100047_bib0695","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib0700","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.drudis.2014.03.016","article-title":"Transcriptional dysregulation in Huntington's disease: a failure of adaptive transcriptional homeostasis","volume":"19","author":"Kumar","year":"2014","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0705","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/brainsci7060063","article-title":"Striatal vulnerability in Huntington's disease: neuroprotection versus neurotoxicity","volume":"7","author":"Morigaki","year":"2017","journal-title":"Brain Sci"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0710","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuron.2010.01.010","article-title":"Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease","volume":"65","author":"Levine","year":"2010","journal-title":"Neuron"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0715","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/1570159X19666211201094608","article-title":"Neuroinflammation in Huntington's disease: a starring role for astrocyte and microglia","volume":"20","author":"Saba","year":"2022","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2006.09.015","article-title":"Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration","volume":"127","author":"Cui","year":"2006","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0725","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0730","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.410310412","article-title":"Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease","volume":"31","author":"Albin","year":"1992","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0735","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ric.2026.100047_bib0740","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fnins.2020.00082","article-title":"Cortical and striatal circuits in Huntington's disease","volume":"14","author":"Blumenstock","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ric.2026.100047_bib0745","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fnsys.2011.00046","article-title":"Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington's disease","volume":"5","author":"Andre","year":"2011","journal-title":"Front Syst Neurosci"},{"key":"10.1016\/j.ric.2026.100047_bib0750","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fnhum.2016.00317","article-title":"Corticostriatal dysfunction in Huntington's disease: the basics","volume":"10","author":"Bunner","year":"2016","journal-title":"Front Hum Neurosci"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0755","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-2012-120009","article-title":"Functional differences between direct and indirect striatal output pathways in Huntington's disease","volume":"1","author":"Galvan","year":"2012","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.ric.2026.100047_bib0760","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.conb.2015.01.020","article-title":"Corticostriatal synaptic adaptations in Huntington's disease","volume":"33","author":"Plotkin","year":"2015","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.ric.2026.100047_bib0765","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnagi.2014.00078","article-title":"Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study","volume":"6","author":"Paulsen","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0770","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0775","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0780","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25657","article-title":"Tracking motor impairments in the progression of Huntington's disease","volume":"29","author":"Long","year":"2014","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0785","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/cont.0000000000001597","article-title":"Huntington disease and chorea","volume":"31","author":"Moore","year":"2025","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinme.2024.100200","article-title":"Huntington's disease: a clinical primer for acute and general physicians","volume":"24","author":"Massey","year":"2024","journal-title":"Clin Med"},{"issue":"19","key":"10.1016\/j.ric.2026.100047_bib0795","doi-asserted-by":"crossref","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","article-title":"Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease","volume":"96","author":"McAllister","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ric.2026.100047_bib0800","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11910-011-0215-x","article-title":"Cognitive impairment in Huntington disease: diagnosis and treatment","volume":"11","author":"Paulsen","year":"2011","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"9","key":"10.1016\/j.ric.2026.100047_bib0805","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/mds.22953","article-title":"Cognitive and functional decline in Huntington's disease: dementia criteria revisited","volume":"25","author":"Peavy","year":"2010","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0810","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00702-024-02744-8","article-title":"Mild cognitive impairment in Huntington's disease: challenges and outlooks","volume":"131","author":"Jellinger","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib0815","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2151","article-title":"Cognitive and behavioral associated changes in manifest Huntington disease: a retrospective cross-sectional study","volume":"11","author":"Migliore","year":"2021","journal-title":"Brain Behav"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0820","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/brainsci7060067","article-title":"Neuropsychiatric burden in Huntington's disease","volume":"7","author":"Paoli","year":"2017","journal-title":"Brain Sci"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0825","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3233\/JHD-180293","article-title":"Clinical management of neuropsychiatric symptoms of Huntington disease: expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders","volume":"7","author":"Anderson","year":"2018","journal-title":"J Huntingtons Dis"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0830","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3233\/JHD-140127","article-title":"Aggression in Huntington's disease: a systematic review of rates of aggression and treatment methods","volume":"3","author":"Fisher","year":"2014","journal-title":"J Huntingtons Dis"},{"issue":"12","key":"10.1016\/j.ric.2026.100047_bib0835","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","article-title":"Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)","volume":"85","author":"van Duijn","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ric.2026.100047_bib0840","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3389\/fneur.2018.00930","article-title":"The clinical picture of psychosis in manifest Huntington's disease: a comprehensive analysis of the enroll-HD database","volume":"9","author":"Rocha","year":"2018","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0845","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.psychres.2011.05.006","article-title":"Suicidal ideation in Huntington disease: the role of comorbidity","volume":"188","author":"Wetzel","year":"2011","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0850","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3233\/JHD-231523","article-title":"Clinical review of juvenile Huntington's disease","volume":"13","author":"Oosterloo","year":"2024","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0855","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3233\/JHD-180339","article-title":"Clinical presentation and features of juvenile-onset Huntington's disease: a systematic review","volume":"8","author":"Cronin","year":"2019","journal-title":"J Huntingtons Dis"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0860","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2217\/nmt.13.78","article-title":"Differential diagnosis of Huntington's disease: what the clinician should know","volume":"4","author":"Cardoso","year":"2014","journal-title":"Neurodegener Dis Manag"},{"issue":"6\u20137","key":"10.1016\/j.ric.2026.100047_bib0865","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neurol.2015.02.016","article-title":"Guidelines for presymptomatic testing for Huntington's disease: past, present and future in France","volume":"171","author":"Cl\u00e9ment","year":"2015","journal-title":"Rev Neurol (Paris)"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0870","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4329\/wjr.v6.i6.301","article-title":"Neuroimaging in Huntington's disease","volume":"6","author":"Niccolini","year":"2014","journal-title":"World J Radiol"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0875","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3233\/JHD-240016","article-title":"Neuroimaging to facilitate clinical trials in Huntington's disease: current opinion from the EHDN Imaging Working Group","volume":"13","author":"Hobbs","year":"2024","journal-title":"J Huntingtons Dis"},{"issue":"5","key":"10.1016\/j.ric.2026.100047_bib0880","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00259-018-4257-z","article-title":"Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease","volume":"46","author":"Sampedro","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0885","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac309","article-title":"Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity","volume":"4","author":"Caron","year":"2022","journal-title":"Brain Commun"},{"issue":"8","key":"10.1016\/j.ric.2026.100047_bib0890","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0895","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00415-024-12785-4","article-title":"Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington's disease","volume":"272","author":"Bamford","year":"2025","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0900","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's Disease Rating Scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0905","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mdc3.12571","article-title":"Rating scales for motor symptoms and signs in Huntington's disease: critique and recommendations","volume":"5","author":"Mestre","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"24","key":"10.1016\/j.ric.2026.100047_bib0910","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib0915","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajmg.b.31232","article-title":"Indexing disease progression at study entry with individuals at-risk for Huntington disease","volume":"156B","author":"Zhang","year":"2011","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib0920","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3233\/JHD-210475","article-title":"Standardizing the CAP score in Huntington's disease by predicting age-at-onset","volume":"11","author":"Warner","year":"2022","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0925","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/mds.26838","article-title":"Validation of a prognostic index for Huntington's disease","volume":"32","author":"Long","year":"2017","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.ric.2026.100047_bib0930","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/mds.28222","article-title":"Clinical outcomes and selection criteria for prodromal Huntington's disease trials","volume":"35","author":"Langbehn","year":"2020","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib0935","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington's disease: the Integrated Staging System","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0940","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/JHD-220555","article-title":"Applying the Huntington's Disease Integrated Staging System (HD-ISS) to observational studies","volume":"12","author":"Long","year":"2023","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib0945","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v13i2.6279","article-title":"A comprehensive review of pharmacological and non-pharmacological therapies for Huntington's disease","volume":"13","author":"Christodoulou","year":"2025","journal-title":"Med Res Arch"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0950","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","article-title":"The long-term effect of tetrabenazine in the management of Huntington disease","volume":"31","author":"Fasano","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0955","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib0960","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Furr Stimming","year":"2023","journal-title":"Lancet Neurol"},{"issue":"13","key":"10.1016\/j.ric.2026.100047_bib0965","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.3390\/ijms26136220","article-title":"Update on the symptomatic treatment of Huntington's disease: from pathophysiology to clinical practice","volume":"26","author":"Olmedo-Saura","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ric.2026.100047_bib0970","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.neuropsych.20230120","article-title":"Treatment of depression in Huntington's disease: a systematic review","volume":"36","author":"Zadegan","year":"2024","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.ric.2026.100047_bib0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpsychores.2022.111023","article-title":"The effects of antidepressants on depressive symptoms in manifest Huntington's disease","volume":"162","author":"Ogilvie","year":"2022","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.ric.2026.100047_bib0980","doi-asserted-by":"crossref","DOI":"10.1371\/currents.RRN1259","article-title":"An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease","volume":"3","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"issue":"5","key":"10.1016\/j.ric.2026.100047_bib0985","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1212\/WNL.0000000000008887","article-title":"Clinical recommendations to guide physical therapy practice for Huntington disease","volume":"94","author":"Quinn","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0990","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2217\/nmt.11.81","article-title":"Development of guidelines for occupational therapy in Huntington's disease","volume":"2","author":"Cook","year":"2012","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib0995","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2217\/nmt.11.78","article-title":"Management of speech, language and communication difficulties in Huntington's disease","volume":"2","author":"Hamilton","year":"2012","journal-title":"Neurodegener Dis Manag"},{"issue":"23","key":"10.1016\/j.ric.2026.100047_bib1000","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMc2300400","article-title":"Tominersen in adults with manifest Huntington's disease","volume":"389","author":"McColgan","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ric.2026.100047_bib1005","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac149","article-title":"Changes in brain activity with Tominersen in early-manifest Huntington's disease","volume":"4","author":"Hawellek","year":"2022","journal-title":"Brain Commun"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib1010","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/MS9.0000000000004574","article-title":"AMT-130 gene therapy: a promising disease-modifying approach for Huntington's disease","volume":"88","author":"Mwape","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"10.1016\/j.ric.2026.100047_bib1015","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/18796397251399751","article-title":"Huntington's disease clinical trials update: October 2025","volume":"15","author":"Farag","year":"2026","journal-title":"J Huntingtons Dis"},{"issue":"5","key":"10.1016\/j.ric.2026.100047_bib1020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","article-title":"The potential of gene editing for Huntington's disease","volume":"46","author":"Duan","year":"2023","journal-title":"Trends Neurosci"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib1025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1474-4422(18)30391-0","article-title":"Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study","volume":"18","author":"Reilmann","year":"2019","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.ric.2026.100047_bib1030","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41591-025-03920-3","article-title":"Pridopidine in early-stage manifest Huntington's disease: a phase 3 trial","volume":"31","author":"Reilmann","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ric.2026.100047_bib1035","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","article-title":"Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial","volume":"28","author":"Feigin","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ric.2026.100047_bib1040","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13852","article-title":"Dalzanemdor (SAGE-718), a novel investigational N-methyl-d-aspartate receptor positive allosteric modulator: safety, tolerability, and clinical pharmacology in randomized dose-finding studies and an open-label study in Huntington's disease","volume":"17","author":"Koenig","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.ric.2026.100047_bib1045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mdc3.12388","article-title":"Data analytics from Enroll-HD, a global clinical research platform for Huntington's disease","volume":"4","author":"Landwehrmeyer","year":"2017","journal-title":"Mov Disord Clin Pract"},{"issue":"11","key":"10.1016\/j.ric.2026.100047_bib1050","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/mds.29929","article-title":"Epidemiology of Huntington's disease in Latin America: a systematic review and meta-analysis","volume":"39","author":"Medina Escobar","year":"2024","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ric.2026.100047_bib1055","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200344","article-title":"Racial disparities in time to Huntington disease diagnosis in North America: an ENROLL-HD analysis","volume":"14","author":"Mendizabal","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"6","key":"10.1016\/j.ric.2026.100047_bib1060","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"}],"container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837626000148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837626000148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:10:18Z","timestamp":1787577018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034837626000148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0034837626000148"],"URL":"https:\/\/doi.org\/10.1016\/j.ric.2026.100047","relation":{},"ISSN":["0034-8376"],"issn-type":[{"value":"0034-8376","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Huntington's disease in the era of somatic instability, biomarkers, and targeted therapies: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Revista de Investigaci\u00f3n Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ric.2026.100047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubiran.","name":"copyright","label":"Copyright"}],"article-number":"100047"}}